Koen Dierckx | Co-founder and CEO Simabs
simAbs
Koen Dierckx has over 20 years of experience in R&D, pharmaceutical operations and project management. He has an executive MBA and holds a Master’s degree in Civil Engineering and Biochemistry from the University of Leuven. He has worked for Sanofi, where he held several positions in biopharmaceutical operations. He is the founder of Pilot Biologix, a biotechnology company that is investing in valorization, technology transfer and scale up of research results in biotechnology and he is co-founder and CEO of simAbs.
Appearances:
Festival of Biologics Day 1 @ 14:00
The roadmap towards continuous manufacturing and realtime release of biologics
Biomanufacturing is here and it is here to stay. By the early 2030’s the majority of all innovative drug sales will be of a biological subtype. Monoclonal antibodies will dominate the market while gene therapies and gene-modified cell therapies will display a significant growth.
At the same time, pharma companies are continuing to develop more personalized innovative therapies that can significantly improve patient outcomes.
With this transition from the blockbuster small molecule business model towards a more personalized biological medicine in mind, one can wonder about the affordability and profitability for the patient, for the pharmaceutical companies and for society. For example, with an average annual price of a therapeutic antibody of $96,731 and exceeding $100,000 for 34 mAb-indication combinations, the answer to this question is that breakthrough technologies to reduce this cost is crucial.
simAbs believes in a biomanufacturing future with a decentralized model with fully automated, closed and continuous manufacturing systems. Therefore, simAbs has a proprietary and innovative continuous manufacturing platform in order to intensify the bioproduction of therapeutic antibodies. This platform enables to manufacture high quality antibodies in variable amounts at a low cost. This will not only enable personalized medicines to be produced at the point-of-care but also biosimilars to be produced in local national or continental markets.
Inline monitoring instead of off line Quality Control will be a fundamental enabler of realtime release and decentralized manufacturing.
And imagine what the future would be like if a biological product that comes out of the machine could be used the same day? This talk will discuss a roadmap towards this future.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events